IJPSR (2020), Volume 11, Issue 10 **(Research Article)**

INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH

Received on 16 October 2019; received in revised form, 03 February 2020; accepted, 11 March 2020; published 01 October 2020

FORMULATION AND *IN-VITRO* DRUG RELEASE STUDY OF CONTROLLED RELEASE TABLET OF NIMODIPINE

Deepti Singh [*1], Deshvir Singh [1] and Dilip Kumar Chanchal [2]

Agra Public Institute of Technology and Computer Education [1], Artoni, Agra - 282007, Uttar Pradesh, India.
Department of Pharmacy [2], Smt. Vidyawati College of Pharmacy, Jhansi - 284128, Uttar Pradesh, India.

Keywords:

Formulation, *in-vitro* study, Nimodipine control released tablet

Correspondence to Author:
Ms. Deepti Singh

Research Scholar,
Agra Public Institute of Technology and Computer Education Artoni,
Agra - 282007, Uttar Pradesh, India.

E-mail: deepneha761@gmail.com

ABSTRACT: At present more than 200 oral continued/controlled/ expanded/altered discharge details are accessible in the worldwide market. In India, notwithstanding, just constrained items are financially affordable. Making a stride ahead from assembling traditional dose structures, the advancement of controlled drug delivery systems. Controlled drug delivery systems have been created to improve the following arranging of the medication in the body. They can assume a noteworthy job in a focused medication conveyance framework in organ or tissue. In the Controlled medication conveyance framework, more than one instrument might be included at various phases of medication pharmacokinetics and pharmacodynamics profiling. Some medication conveyance frameworks have been planned and are being researched. These sorts of the context had some bit of leeway over common medication conveyance framework, including a brief time of medication discharge insurance of flimsy medications and expanded patient solace and consistency. The audit underlines the technique of controlled medication conveyance framework planning, their criticalness, burdens, point by point order, and the pertinent model any place required are illustrated. This audit will give knowledge to scientists and academicians, an instant update on the theme. In this, an alternate strategy and various procedures are included.

INTRODUCTION: Oral route as been one of the most prominent generally utilized courses of medication conveyance because of its simplicity of organization, tolerant consistency, least sterility limitations, the adaptable structure of measurement structures, and cost adequacy to assembling process [1].

QUICK RESPONSE CODE

DOI: 10.13040/IJPSR.0975-8232.11(10).5027-38

The article can be accessed online on www.ijpsr.com

DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.11(10).5027-38

Tablets are the most well known oral details accessible in the market and favored by patients and doctors the same. This sort of medication conveyance framework is called a customary medication conveyance framework and is known to give a quick arrival of medication.

Such prompt discharge items bring about generally fast medicate ingestion and the beginning of going with pharmacodynamic impacts. Nonetheless, after the assimilation of medication from the structure of the measurement is finished, plasma sedate focuses decrease as per the medication's pharmacokinetic profile.

In the long run, plasma tranquilizes fixations fall beneath the base successful plasma focus (MEC), bringing about loss of helpful movement [2]. Before this point has arrived at another portion is generally given if a continued remedial impact is wanted. These measurement structures have been found to have the accompanying genuine confinements.

- Inconvenient due to periodic administration
- Difficult to monitor.
- Non-specific administration.
- Careful count important to avert overdosing.
- Drug goes to non-target cells and can cause harm.
- Low fixations can be inadequate.

Oral Controlled Drug Delivery System: An option in contrast to the organization of another portion is to utilize the structure of a measurement that will give supported medication discharge, and along these lines, keep up plasma sedate focuses.

Oral broadened discharge medicates conveyance framework turns into an exceptionally encouraging methodology for those medications that are given orally yet having the shorter half-life and high dosing recurrence. Controlled discharge definitions are much alluring and favored for such treatment since they offer better tolerant consistency, keep up uniform medication levels, decreased portion and symptoms, and expanded edge of wellbeing for high-intensity drugs [3].

A perfect dose structure for the treatment of any illness is the one that promptly achieves a helpful plasma level and keeps up it steady for the whole time of treatment. This is conceivable through the organization of traditional measurement structure at a specific recurrence.



FIG. 1: PLASMA DRUG CONCENTRATION-TIME PROFILE OF CONVENTIONAL, ZERO ORDER AND SUSTAINED RELEASE DOSAGE FORMS

In any case, with a customary dose structure, there is unavoidable variance in the medication plasma level, which can be overwhelmed by the utilization of support discharge measurement structure [4]. Plasma drug concentration profiles for conventional tablet formulation, a sustained release formulation, and zero-order controlled discharge formulation are shown in **Fig. 1**.

MATERIALS AND METHODS:

Materials: Various chemicals, solvents, instruments, and glassware are used during project work are listed below in **Table 1** and **Table 2**.

TABLE 1: LIST OF CHEMICALS

S. no.	Chemicals	Source
1	Nimodipine	Yarrow Chem, Mumbai
2	Methocel	New Delhi
3	Carboxy methyl cellulose	New Delhi
4	Methanol	Roorkee
5	Cellulose Acetate	New Delhi
6	Microcrystalline Cellulose	New Delhi
7	Magnesium stearate	New Delhi
8	Aerosil	New Delhi

TABLE 2: LIST OF EQUIPMENT

S. no.	Equipment	Source
1	UV-spectrophotometer	Model 1700, Shimadzu, Japan
2	FTIR spectrophotometer	Perkin Elmer, Singapore, pvt, Ltd.
3	Melting point apparatus	Jyoti Scientific Industries, Gwalior
4	Electronic balance	Roy Electronics, India
5	Tray Dryer	Erweka Pvt. Ltd.
6	Dissolution Apparatus (USP) Auto Sampler	Electrolab Pvt. Ltd.
7	Tablet Hardness tester	Monsanto
8	Friability test apparatus	Electrolab Pvt. Ltd. EF 2 USP
9	pH meter	VSI-IB, VSI Electronics, India
10	Vernier Caliper	Digimatic
11	Tablet punching machine	CADMACH 16 station

Formulation Development and Characterization:

Pre-optimisation Studies:

Optimization of Polymer Concentration: For fixing the desired range of variables (polymer focus) required for the last detailing, a pre-improvement study was directed with various convergences of polymers. As the grouping of polymers changed, there was an immediate impact on swelling records and medication discharge. Tablets were readied utilizing grouping of polymers structure low to high in each clump. HPMC various evaluations and CMC were utilized as polymers for hindering the medication discharge. Small scale crystalline cellulose was utilized as filler as the tablets were set up by direct pressure. Powder and Magnesium stearate were utilized as grease and glidant.

Formulation Development:

Preparation of Matrix Tablets of Nimodipine Wet Granulation Method: Nimodipine (30 mg) network tablets were set up by blending the medication with different groupings of polymers (for example, HPMC (different evaluations), CMC and other excipient resemble miniaturized scale crystalline cellulose, magnesium stearate, and so on in a polythene sack. Tablets were set up by a direct pressure system for which the arranged powder mix was sieved through strainer no 40 and dried in a tourist oven beneath 60 ºC. Powder mix was then blended with magnesium stearate and aerosil to get it greased up, which was then compacted into tablets in a rotating tablet pressure machine utilizing 12 mm caplet punches. Before pressure, the surfaces of the kicks the bucket and punches were greased up with magnesium stearate. Arranged tablets were put away in a water/air proof holder at room temperature for further examinations.

Preparation of 5% Cellulose Acetate (CA) Film: To 100 ml of $(CH_3)2CO$, 5 g of cellulose acetic acid derivation was bit by bit included. After all the cellulose acetic acid derivation was included, the arrangement was mixed for 2 h to totally disintegrate the CA. The CA arrangement was degassed for 3 h, and it is prepared for covering.

TABLE 3: FORMULATION OF BATCH T-1 TO T-5

S. no.	Ingredients	NMP 1	NMP 2	NMP 3	NMP 4	NMP 5
1	Nimodipine	30	30	30	30	30
2	HPMC K4M	15	20	25	X	X
3	HPMC K15M	X	10	X	15	20
4	HPMC K100M	X	X	X	X	X
5	CMC	X	X	X	X	X
6	MCC	58	66	64	58	64
8	Mg Stearate	6	6	6	6	6
9	Aerosil	q.s	q.s	q.s	q.s	q.s

TABLE 4: FORMULATION OF BATCH T-6 TO T-10

S. no.	Ingredients	NMP 6	NMP 7	NMP 8	NMP 9	NMP 10
1	Nimodipine	30	30	30	30	30
2	HPMC K4M	X	25	X	X	X
3	HPMC K15M	25	X	X	X	X
4	HPMC K100M	X	15	20	25	20
5	CMC	X	X	X	X	50
6	MCC	66	64	58	66	64
8	Mg Stearate	6	6	6	6	6
9	Aerosil	q.s	q.s	q.s	q.s	q.s

Evaluation of Tablets: [5]

Bulk Density:

Loose Bulk Density: An accurate amount of powder was moved to a 10 ml estimating chamber, and the volume involved by the powder regarding ml was recorded.

Loose bulk density (LBD) = Weight of powder in gm / Volume packed in ml

Tapped Bulk Density: Loosely packed powder in the chamber was tapped multiple times on a plane hard surface and volume involved in ml was noted.

Tapped bulk density (TDB) = Weight of powder in gm / Tapped volume in ml

Hausner's Ratio: The number is identified with the flowability of powder or granules.

A Hausner's proportion of <1.25 demonstrates a powder that is free streaming though >1.25 shows poor stream capacity.

$$\text{Hausner's ratio} = \text{TDB} / \text{LDB}$$

Carr's Compressibility Index: It means that the compressibility of a granule or powder. In pharmaceutics, it means the flowability of the powder. Carr's record with worth more than 25 is viewed as a sign of low flowability, and under 25 is having great stream property. The littler Carr's file the better the stream properties. For instance 5-15 shows fantastic, 12-16 great, 18-21 reasonable and > 23 poor stream.

Angle of Repose: A funnel is fixed and is verified with its tip at a stature (h) of 2 cm above diagram paper, which is put on a level surface. The powder is dropped, and the span (r) is estimated. Edge of rest can be estimated by the accompanying condition

$$\Theta = \tan^{-1} (h/r) \text{ or } \text{Tan } \Theta = h / r$$

Values ≤ 30 indicates free-flowing powder, and 30 ≥ 40 are poor flowing powders.

Evaluation of Physical Properties of Matrix Tablets: [6]

Thickness and Diameter: 10 tablets were haphazardly picked from each clump, and their thickness and width were estimated utilizing an aligned dial Vernier caliper (± 5% is permitted).

Weight Variation Test: 20 tablets were haphazardly chosen from each clump and burdened an electronic equalization. Weight of 10 tablets and individual tablets were taken; their mean and standard deviation of weight were determined from each group.

Hardness Test: 10 tablets were haphazardly chosen from each group, and the hardness of every tablet was controlled by utilizing a Pfizer type hardness analyzer. The mean standard deviation was determined for each group.

Friability Test: It is the capacity of tablets to withstand mechanical stuns while taking care of and transportation. 10 tablets were chosen haphazardly from each clump and gauged and put in a friability test mechanical assembly and worked at a speed of 25 rpm for 4 min. Tablets were gathered and weighed once more. The loss of tablet weight was determined and estimated as far as % friability. Adequate estimation of friability is under 1

$$F = [(W_{initial} - W_{final}) \times 100] / W_{initial}$$

Swelling Index of Matrix Tablets: The swelling property of grid tablets was estimated as far as rate weight gain by the tablet. The swelling conduct of all plans was contemplated. One tablet from every definition was kept in a petridish containing pH 7.4 phosphate cradles. Toward the part of the arrangement and 1 h, the tablets were pulled back and doused with tissue paper, at that point gauged. At that point, after every hour, the weight of tablets was gauged and proceeded till 8 h rate weight increase of tablets was determined by equation [5].

$$S.I = \{(M_t - M_o) / M_o\} \times 100$$

Where, S.I = swelling index, M_t = weight of tablet at time t (h), M_o = weight of tablet at zero time.

Drug Content Estimation: [7]

A. Standard Solution: 100 mg of unadulterated Nimodipine (tranquilize) was broken down in the water in a volumetric jar, and the volume was made sufficient and sonicated for 5 min.

B. Sample Solution: 20 tablets from each clump were arbitrarily chosen and gauged precisely and finely powdered. To a powder equal to 100 mg of Nimodipine, about 70 ml of water was included and broke up with the guide of shaker for 15 min; at that point, the adequate amount of water was added to deliver 100 ml in a volumetric carafe, blended well and sifted.

To 1 ml of the filtrate, methanol was added to create 100 ml and blended well. The absorbance of the subsequent arrangement was estimated at 233 nm utilizing a standard arrangement as clear. This test was directed in triplicate.

***In-vitro* Release Studies:**

Preparation of Standard curve for Nimodipine:

Preparation of Standard Stock Solution: Accurately weighed 30 mg of Nimodipine and moved into a 100 ml volumetric cup, broke up in 50 ml of refined water, and made up to acquire a standard stock arrangement of 1000 µg/ml sedate focus.

From this Standard stock arrangement of Nimodipine, 100 µg/ml (Stock Arrangement) was set up by pipetting 10 ml of a stock answer for a 100 ml volumetric carafe and making up to 100 ml with refined water.

Determination of Wavelength of Maximum Amplitude (D2 value) of Nimodipine: 10 ml of the above arrangement was weakened to 100 ml with a similar dissolvable to get 10 µg/ml of fixation. The UV range of definite arrangement was filtered in the scope of 200 – 400 nm against refined water as clear. The λ_{max} was found at 233.8 nm.

STD Curve of Nimodipine: One mille liter (1 ml) of the standard stock arrangement was taken and weakened to 10 ml with refined water (100 µg/ml), from the above arrangement 0.2, 0.4, 0.6, 0.8 and 1 ml were pipetted out and weakened to 10 ml with refined water to get the last grouping of 2, 4, 6, 8 and 10 µg/ml individually.

In-vitro release studies of arranged lattice tablets and advertised medication were directed for a time of 12 h utilizing an eight-station USP XXII sort I mechanical assembly at 37 ± 0.5 ºC; the speed of bin was set at 100 ± 1 rpm. In every flagon, 900 ml supported media (pH 6.8) was utilized as disintegration media.

An aliquot (5 ml) was pulled back at each 1 h interim and supplanted with a new medium to keep up sink condition. Tests were sifted through Whatman channel paper no. 1 and weakened suitably and dissected at 233 nm by twofold bar UV/noticeable spectrophotometer utilizing disintegration medium as clear. Investigations were executed as n = 3. The measure of medication present in the examples was determined by utilizing the alignment bend built from a reference standard.

Drug Release Kinetics: The drug release kinetics were considered by different active models, for example, Korsmeyer-Peppas, Higuchi plot, first request plot, and zero request plot. To consider the discharge energy, information got from *in-vitro* medication discharge studies were plotted in different dynamic models: zero requests as a total measure of medication discharged versus time, the first request as log aggregate level of medication remaining versus time, and Higuchi's model as the total level of medication discharged versus square base of time [8].

The best fit model was affirmed by the estimation of the connection coefficient close to 1. The information was displayed for the most suitable model.

Zero Order: Graph plotted between the total measure of medication discharged versus time

$$C = K_0\, t \text{.....Eqn (1)}$$

Where K0 is the zero-request rate consistently communicated in units of fixation/time, and t is the time in hours. A chart of focus versus time would yield a straight line with a slant equivalent to K0 and block the cause of the tomahawks.

First Order: Graph was plotted between log aggregate levels of medication remaining versus time

$$\text{Log } C = \text{Log}C_0 - kt/2.303 \text{.....Eqn (2)}$$

Where C0 is the initial concentration of the drug, k is the first order constant, and t is the time.

Higuchi's Model: Graph was plotted between combined levels of medication discharged Versus square base of time.

$$Q = K_t 1/2 \text{.....Eqn (3)}$$

Where K is the steady mirroring the plan factors of the framework, and t is the time in hours. Henceforth, the tranquilize discharge rate is corresponding to the proportionality of the square base of time.

Korsmeyer-Peppas: The dissolution data were additionally fitted to the outstanding Korsmeyer Peppas condition (as log total level of medication discharged Versus log time), which is regularly used to depict the medication discharge conduct from polymeric frameworks and the example n was determined through the slant of the straight line.

$$M_t / M_\infty = Ktn \text{ or } \log Mt / M\infty = \log K + n\log t \text{..... Eqn (4)}$$

Where, M_t/M_∞ is the partial solute discharge, Mt is the measure of medication discharged at time t, M_∞ is the measure of medication discharge after endless time, t is the discharge time, K is an active

discharge rate steady normal for the medication/polymer framework, and n is the diffusional example that describes the system of medication discharge.

If the exponent n = 0.45, then the drug release mechanism is Fickian diffusion, and if 0.45 < n < 0.89, then it is non-Fickian or anomalous diffusion. An exponent value of 0.89 is indicative of Case-II Transport or typical zero-order release.

Similarity Factor: Similarity factor (f2) is a logarithmic proportional square root change of the aggregate of squared mistake and is an estimation of the likeness in rate (%) disintegration between two bends. To assess and think about disintegration information, the disintegration information is factually dissected utilizing disintegration similitude factor. Comparability factor can be discovered by utilizing the accompanying condition [9].

$$f_2 = 50\log\left\{\left[1+\frac{1}{n}\sum_{t=1}^{n}(R_t - T_t)^2\right]^{-0.5} \times 100\right\}$$

Where n = number of dissolution time points. Wt = Optional weight factor. R_t = Reference dissolution point at time t. T_t = Test dissolution point at time t.

The f2 factor somewhere in the range of 50 and 100 recommends that the disintegration is comparable, and the f2 qualities going from 100 propose that the two disintegration profiles are comparable, while the littler qualities recommend that they are not comparative.

Stability Studies: It is defined as "the capacity of a drug product to remain inside the particulars set up to guarantee its personality, quality, and immaculateness". It tends to be just clarified as the capacity of a medication to oppose crumbling".

Short-Term Stability Study: Was performed at temperature 40 ± 2 ºC over a time of a quarter of a year on the framework tablet (MFH 14). An adequate number of tablets (10) were pressed in golden-hued screw-topped jugs and kept in strength chamber kept up at 40 ± 2 ºC. Tests were taken at one month interim for medication content estimation. Toward the part of the arrangement, tablets were assessed for medication content, rate friability, swelling file, and disintegration test to decide the medication discharge profiles.

Long-Term Stability Study: Was performed at a temperature of 25 ± 2 ºC 60% ± 5% RH over a time of a year on the lattice tablet (MFH 14). An adequate number of tablets (10) were stuffed in golden head screw-topped jugs and kept in the soundness chamber kept up at 25 ± 2 ºC. Tests were taken at 0, 3, 6, 9, and year interim for medication content estimation. On each predefined interim, tablets were assessed for medication content, rate friability, swelling list and disintegration test to decide the medication discharge profiles.

RESULTS AND DISCUSSION:

Pre-Optimisation Studies:

Optimization of Polymer Concentration: Matrix tablets of Nimodipine were set up in each bunch utilizing diverse centralization of polymers, for example, from lower to higher focus. The planned tablets were assessed for its swelling file and medication discharge at NMP 1, NMP3, and NMP 9. The grouping of polymers and its impact on reaction factors fixed the higher and lower convergence of polymers.

The higher convergence of different evaluations of HPMC was chosen as it gave progressively controlled arrival of medication with an adequate swelling list and medication discharge at NMP 1, NMP3, and NMP 9.

Among NMP 1, NMP 3, and NMP 9, NMP 9 was chosen as it gave the ideal discharge and swelling list design when contrasted with others. NMP 10 was set up by utilizing a blend of HPMC K100M and CMC so as to decrease the burst discharge at Q2 interim. These outcomes can be contrasted and R. Charulatha *et al.,* in 2012, which expresses that HPMC K100M with Na CMC was viable in impeding the discharge as the polymer proportion expanded.

Design and Preparation of Swelling Restricted Matrix Tablet of Nimodipine: Tablets NMP 9 were chosen as they met the fixed parameters of discharge and swelling file. This definition was changed over to swelling limited network tablet by incompletely covering them with 5% cellulose

acetic acid derivation arrangement. Thusly, there swelling was confined and consequently, discharge was additionally impeded and furthermore, no investigations were found in writing to look at it.

Evaluation of Flow Properties of Powder: Powders prepared for direct compression method were evaluated by estimating the accompanying parameters, for example, bulk density, angle of repose, Hausner's factor, compressibility index, and drug content. The outcomes have appeared in **Table 5**.

TABLE 5: VALUES OF PRE – COMPRESSION PARAMETERS OF DEVELOPED FORMULATIONS, N = 3

S. no.	LBD (gm/cc)	TBD (gm/cc)	Hausner's Factor	Carr's compressibility Index (%)	Angle of repose (º)
NMP 1	0.431	0.544	1.25	19.60	21.54±0.012
NMP 2	0.425	0.522	1.22	18.42	22.53±0.013
NMP 3	0.415	0.506	1.24	19.01	25.34±0.021
NMP 4	0.434	0.523	1.22	18.21	23.71±0.026
NMP 5	0.427	0.537	1.24	17.04	24.33±0.069
NMP 6	0.427	0.526	1.23	19.31	24.43±0.010
NMP 7	0.412	0.510	1.24	20.01	22.74±0.040
NMP 8	0.429	0.532	1.22	19.05	25.10±0.062
NMP 9	0.438	0.529	1.23	19.11	23.34±0.042
NMP 10	0.427	0.537	1.24	17.12	25.24±0.064

Angle of Repose: The result of angle of repose (<30) demonstrate great stream properties and the qualities for arranged plans ranges from 21.54 – 25.34.

Hausner's Factor: The values of Hausner's factor were under satisfactory range.

Compressibility Index: the values up to 15% outcomes were in great to brilliant stream properties and estimations of all definitions ranges from 17.04 – 20.01%.

Drug Content: the values of all the formulations were in the range from 97.48% - 99.83%. All these results obtained indicated that the granules possessed satisfactory flow properties, compressibility and uniform drug content.

Evaluation of Tablets:

General Appearance: The formulated tablets were evaluated for its organoleptic qualities as appeared in **Table 6**.

TABLE 6: OBSERVATIONAL REPORT OF VARIOUS PARAMETERS OF TABLETS

Parameters	Observation
Shape	All tablets remained in caplet shape with no visible cracks.
Colour	Off white
Odour	No characteristic odour
Appearance	All tablets were elegant in appearance

Hardness: Normally for oral tablets the hardness range is in the middle of 5 - 10 kg/cm^2. Hardness of the tablets was tried utilizing Pfizer type hardness analyzer and the outcomes are appeared in **Table 6.11.** Hardness of the considerable number of tablets was inside as far as possible for example from 5.23 kg/cm^2 - 5.87 kg/cm^2.

Thickness: All formulated tablets were evaluated for uniformity of thickness utilizing a Vernier calliper and the outcomes are appeared in Table 6.11. The thickness of all the defined tablets was in the scope of 3.20 ± 2.00 mm.

Weight Variation Test: The test was performed as per the official method. Twenty tablets from each group were chosen haphazardly and separately gauged. Every tablet was assessed for rate deviation and their outcomes are appeared in **Table 7**. Passable rate deviation for arranged tablets are ± 5% for weight in excess of 324 mg.

Friability Test: The apparatus used for conducting friability test was Roche friabilator. Pre-gauged 10 tablets were taken and stacked into the contraption and the insurgency speed was changed in accordance with 100. After 100 upsets the tablets were cleaned and reweighed.

The outcomes are appeared in **Table 7**. The adequate weight reduction for tablets ought not be over 1% of the heaviness of tablets. The friability of all tablets was inside as far as possible, which demonstrated that there was a decent grip property between the excipients utilized in the definition.

Drug Content: The percentage content of Nimodipine in the plan was assessed at 234 nm utilizing spectrophotometer. The point of confinement for substance consistency ought to be in the scope of 90 - 110% and the outcomes demonstrated that substance consistency of Nimodipine in the detailing was between 97.48 ± 0.54 - 99.83 ± 0.72% **Table 7**, which is inside as far as possible.

TABLE 7: RESULTS OF POST-COMPRESSION PARAMETERS

Batch	Hardness	Thickness	% Friability	Weight variation	%Drug content
NMP 1	5.24	3.38	0.81	201 ± 0.59	99.53
NMP 2	5.04	3.59	0.76	198 ± 0.63	98.25
NMP 3	5.59	3.79	0.63	202 ± 0.45	99.38
NMP 4	5.21	3.53	0.58	200 ± 0.45	98.68
NMP 5	5.49	3.72	0.59	201 ± 0.45	97.48
NMP 6	5.51	3.51	0.63	204 ± 0.45	98.57
NMP 7	5.32	3.63	0.66	203 ± 0.45	98.35
NMP 8	5.55	3.42	0.61	205 ± 0.45	99.53
NMP 9	5.56	3.51	0.55	200 ± 0.45	99.53
NMP 10	5.77	3.62	0.64	200 ± 0.45	98.39

***In-vitro* Dissolution Studies:**

Preparation of Calibration Curve: Calibration curve of Nimodipine was plotted with concentration in X-axis and absorbance in Y-axis **Fig. 2**.

TABLE 8: ABSORBANCE VALUES OF NIMODIPINE IN DISTILLED WATER

Concentration (µg/mL)	Absorbance at 236 nm
2	0.1914
4	0.4187
6	0.5465
8	0.7372
10	0.9154



FIG. 2: ABSORBANCE VALUES OF NIMODIPINE IN DISTILLED WATER

***In-vitro* Drug Release Studies:** The results of cumulative percentage of drug release are given in the **Table 9** and **Table 10** which unmistakably demonstrated that the discharge rate and rate medication discharge demonstrated a wide variety. From the acquired outcome it was comprehended that the medication discharge was firmly influenced by the convergence of polymer in the plan. The lattice tablet during swelling is a total mass of water swollen polymer, medicate and excipients which encounters different level of hydration. The strong substance in the tablet of different districts fluctuated from 0 – 100%. The territory of 100% strong was only a wetted mass of powder. At the point when the water substance of wetted mass expanded the polymer wound up hydrated and framed a gel. In the furthest layer the polymer had no basic uprightness and thus got disintegrated.

Formulations fabricated with different grades of HPMC alone for example MFH1 – MFH 9 demonstrated an underlying burst discharge however discharge was hindered by expanding the convergence of polymer, which might be because of the arrangement of a thick gooey gel layer around the tablet.

Among these definitions (MFH 1 – MFH 9), the best plan for example MFH 9 was chosen and treated with blend of HPMC K100M and CMC in various proportions (MFH 10 – MFH 12), which brought about a diminishing in the underlying burst discharge and thus an all the more impeding impact was watched. From NMP 9 – NMP 10 details MFH 9 was chosen as there was a decline in the medication discharge, especially at Q2 H interim and was changed over to swelling limited framework tablet (NMP 11 and NMP 12), where the discharge was all the more adequately impeded to the ideal recurrence.

TABLE 9: *IN-VITRO* %CDR OF DRUG FROM NIMODIPINE MATRIX TABLETS NMP 1 TO NMP 6 (N =3)

Time in h	NMP 1	NMP 2	NMP 3	NMP 4	NMP 5	NMP 6
1	45.00 ± 0.577	34.07 ± 0.581	27.00 ± 0.635	42.74 ± 0.491	25.64 ± 0.670	25.07 ± 0.581
2	59.20 ± 0.325	41.25 ± 0.557	31.44 ± 0.694	48.47 ± 0.664	42.02 ± 0.578	32.28 ± 0.582
3	62.09 ± 0.550	46.55 ± 0.652	40.58 ± 0.462	56.38 ± 0.665	48.45 ± 0.557	41.21 ± 0.532
4	67.49 ± 0.550	53.05 ± 0.580	46.78 ± 0.665	62.46 ± 0.559	57.09 ± 0.585	46.65 ± 0.614
5	71.09 ± 0.550	61.15 ± 0.522	58.48 ± 0.580	70.36 ± 0.560	62.81 ± 0.724	57.52 ± 0.553
6	76.56 ± 0.606	54.82 ± 0.318	62.06 ± 0.580	76.21 ± 0.723	70.77 ± 0.722	63.02 ± 0.578
7	83.70 ± 0.665	71.64 ± 0.664	66.56 ± 0.580	78.06 ± 0.581	75.12 ± 0.590	71.06 ± 0.580
8	87.26 ± 0.696	76.09 ± 0.585	71.06 ± 0.580	81.40 ± 0.666	79.51 ± 0.609	77.33 ± 0.668
9	90.93 ± 0.521	80.78 ± 0.434	80.06 ± 0.617	84.40 ± 0.723	83.35 ± 0.486	81.03 ± 0.578
10	97.90 ± 0.458	87.05 ± 0.580	86.26 ± 0.617	93.31 ± 0.724	89.03 ± 0.578	85.46 ± 0.638

TABLE 10: *IN-VITRO* %CDR OF DRUG FROM NIMODIPINE MATRIX TABLETS NMP 7 TO NMP 12 (N =3)

Time in h	NMP 7	NMP 8	NMP 9	NMP 10	NMP 11	NMP 12
1	23.30 ± 0.723	22.20 ± 0.917	25.07 ± 0.581	21.40 ± 0.700	22.30 ± 0.700	20.73 ± 0.433
2	39.28 ± 0.676	33.03 ± 0.578	37.44 ± 0.747	36.77 ± 0.754	36.01 ± 0.577	34.07 ± 0.582
3	51.08 ± 0.583	36.09 ± 0.584	49.21 ± 0.740	48.22 ± 0.646	40.38 ± 0.583	38.85 ± 0.522
4	55.59 ± 0.621	47.98 ± 0.591	54.82 ± 0.725	53.05 ± 0.580	46.95 ± 0.580	47.61 ± 0.552
5	61.56 ± 0.617	54.89 ± 0.948	61.09 ± 0.584	59.19 ± 0.641	58.52 ± 0.405	60.28 ± 0.550
6	68.11 ± 0.588	61.86 ± 0.940	65.66 ± 0.810	65.03 ± 0.611	64.32 ± 0.439	66.07 ± 0.581
7	74.17 ± 0.639	69.32 ± 0.659	70.12 ± 0.611	71.78 ± 0.755	68.32 ± 0.496	71.06 ± 0.580
8	77.78 ± 0.722	72.41 ± 0.463	72.03 ± 0.578	75.12 ± 0.589	73.80 ± 0.724	75.53 ± 0.611
9	82.42 ± 0.741	76.43 ± 0.869	76.33 ± 0.704	80.66 ± 0.882	78.08 ± 0.583	79.09± 0.585
10	87.16 ± 0.617	79.09 ± 0.585	81.03 ± 0.578	89.03 ± 0.578	84.11 ± 0.588	85.56 ± 0.549



FIG. 3: *IN-VITRO* %CDR OF DRUG FROM NIMODIPINE MATRIX TABLETS NMP 1 TO NMP 6



FIG. 4: *IN-VITRO* %CDR OF DRUG FROM NIMODIPINE MATRIX TABLETS NMP 7 TO NMP 12

Release Kinetic Model: To find out the drug release from the obtained data, every one of the information were fitted into different motor models, for example, zero request, first request and higuchi model. Straight relapse investigation was accomplished for every one of the groups and their outcomes are appeared in the accompanying **Table 11**. The higuchi square foundation of time model had the higher r^2 values which when contrasted with zero request and first request active models demonstrated that they pursued higuchi model. Further, to understand the drug release mechanism, the information was fitted in to peppas model and the got 'n' values demonstrated the medication transport component. From the got information for peppas model, 'n' values were inside the scope of 0.5 <n< 1.0 as appeared, which unmistakably demonstrated that the medication discharge pursued non - fickian peculiar vehicle dispersion system which is tantamount to an examination done by T. Raja Sekharan *et al.*, in 2011 clarified discharged dynamic pursued korsmeyers peppas model and component of medication discharge was non- fickian for the planning of HPMC based controlled release matrix tablet.

The Pre-compression and post compression in this study were inside worthy cut off points. Information was fitted into different active models which were tantamount to an investigation done by Mohammed Raquibul Hasan *et al.*, in 2014 for the readiness of ER Nimodipine.

TABLE 11: CORRELATION COEFFICIENT VALUES AND RELEASE KINETICS OF NIMODIPINE MATRIX TABLETS

Formulation	Zero order		First order	
	AVG k	AVG r^2	AVG k	AVG r^2
NMP 1	4.7751	0.9637	-0.3372	0.8951
NMP 2	5.6638	0.9961	-0.2394	0.8642
NMP 3	6.3877	0.9919	-0.2400	0.8709
NMP 4	5.0957	0.9788	-0.3068	0.8537
NMP 5	6.1117	0.9685	-0.2900	0.8588
NMP 6	6.4548	0.9845	-0.2262	0.9484
NMP 7	5.9096	0.9635	-0.2679	0.8669
NMP 8	6.0788	0.9619	-0.2519	0.8985
NMP 9	5.9328	0.9638	-0.1673	0.9762
NMP 10	5.2974	0.9507	-0.1634	0.9699
NMP 11	6.3020	0.9698	-0.2406	0.9281
NMP 12	6.2578	0.9810	-0.2106	0.9403

TABLE 12: CORRELATION COEFFICIENT VALUES AND RELEASE KINETICS OF NIMODIPINE MATRIX TABLETS

Formulation	Higuchi model		Peppas model	
	AVG k	AVG r^2	AVG n	AVG r^2
NMP 1	0.2218	0.9851	0.3192	0.9818
NMP 2	0.2605	0.9884	0.4367	0.9785
NMP 3	0.2937	0.9836	0.5463	0.9771
NMP 4	0.2365	0.9891	0.3568	0.9798
NMP 5	0.2863	0.9967	0.5196	0.9936
NMP 6	0.2992	0.9924	0.5679	0.9899
NMP 7	0.2762	0.9873	0.5003	0.9888
NMP 8	0.2854	0.9947	0.5421	0.9876
NMP 9	0.2777	0.9908	0.5804	0.9902
NMP 10	0.2498	0.9914	0.4920	0.9903
NMP 11	0.2946	0.9942	0.5762	0.9894
NMP 12	0.2908	0.9937	0.5722	0.9935

Stability Studies: Short term stability study: Accelerated stability studies were conducted to prove how the fabricated tablets may change as for time affected by natural variables like temperature and moistness. According to the rules, momentary security study was led for a time of a half year with the temperature at 40 ± 2 ºC and 75 ± 5% relative mugginess. It indicated insignificant changes in regard to appearance, sedate substance, dis-integration, and measure. The got outcomes have appeared in **Table 13**.

TABLE 13: RESULTS OF SHORT TERM STABILITY STUDY OF NMP12

Evaluation	NMP 12		Nimodip	
Colour	Off white		No change	
Drug content %	99.63 ± 0.53		99.56 ± 0.48	
Swelling index	Q2 (h)	Q8 (h)	Q2 (h)	Q8 (h)
	20.0%	58.82%	21.2%	58.67%
Hardness	5.63		5.60	
Friability	0.53%		0.60%	

Long Term Stability Study: According to the rules, long haul solidness study was directed for a time of a year with temperature at 25 ± 2 ºC and 60 ± 5% relative stickiness. It demonstrated unimportant changes in regard to appearance, tranquilize substance, disintegration and measure. The got outcomes are appeared in Table 14. Enhanced plans are viewed as steady as they were impressively steady even after the capacity of a year and there was no change from the underlying test of 5% or more. This affirmed the definitions were steady during the strength study period. A comparable investigation was found in the writing by Abdelkader H *et al.,* in 2007 and Mohammed Abdul Hadi *et al.,* in 2012 found that there were no critical changes in medication content after steadiness reads for enhancedplan.

TABLE 14: RESULTS OF LONG TERM STABILITY STUDY OF NMP 12

Evaluation	0 Month		12 Month	
Colour	Off white		No change	
Drug content %	99.63 ± 0.53		95.56 ± 0.47	
	Q2 (h)	Q8 (h)	Q2 (h)	Q8 (h)
Swelling index	20.0%	58.82%	22.6%	60.15%
Hardness	5.63		5.85	
Friability	0.53%		0.84%	

Similarity Factor: The similarity factor of formulation NMP 12 when compared with reference formulation was 70.228.

DISCUSSION: The study was undertaken with an aim to formulate development, and evaluation of the Preformulation investigation of Nimodipine was done at first, and results coordinated for the further course of detailing. In view of pre-formulation ponders, various clumps were readied utilizing chose excipients. At first, concoction communications were discovered utilizing Fourier change infrared spectrophotometer and Differential filtering calorimetry.

From the examination, it was presumed that there was no substance communication between the medication and the excipients utilized for the detailing of grid tablets, and simultaneously, the medication existed in crystalline nature and didn't change to its shapeless structure. From the pre-optimization studies, it could be concluded that lower and higher concentrations of polymers gave undesired release patterns. It helped in fixing the proportion of polymers in conclusive clumps of details, which gave adequate swelling records and discharge designs.

The impact of the various proportion of polymers was examined, and it obviously demonstrated that the medication discharge rate for the whole group had a wide variety. The outcomes obviously demonstrated that the medication discharge was firmly influenced by the polymers chosen for the investigation. It was assessed for tests LOD, Mass thickness, tapped thickness, compressibility record, Hausner proportion before being punched as tablets.

Tablets were tried for weight variety, thickness, hardness, and friability according to official methodology. The disintegration of cluster T-8 was completed in 6.8 pH media and contrasted and advertised arrangement. In view of disintegration tests and F-2 qualities in pH 6.8 phosphate support as discharge medium, it was reasoned that T-8 agreeable performs in a similar way as that of showcased definition. F-2 (likeness factor) estimation of T-6 was observed to be 73.90.

The obtained pre-compression and post-compression study data revealed that the prepared tablets comply with the requirements necessary to pass an official quality control test. The findings from the disintegration study uncovered that hydrophilic network tablet of HPMC K100M alone couldn't hinder the arrival of Nimodipine as it gave an underlying burst discharge at Q2 interim. This bursting discharge was constrained by consolidating with CMC, which impeded the discharge pace of Nimodipine from the frameworks and diminished the burst discharge at Q2 interim. A moderate and consistent discharge was accomplished by covering the best definition (MFH12 with cellulose acetic acid derivation 5% arrangement and a swelling limited framework tablet was created.

By changing over to swelling confined framework tablet, the discharge was additionally impeded, and the underlying burst discharge at Q2 interim was controlled successfully, and the fixed parameters were accomplished. Discharge motor models uncovered that medication discharge profiles of all definitions affirmed the Higuchi model and pursued non – fickian dispersion transport. MFH 14 was taken as the advanced plan where dispersion combined with disintegration could be the system for medication discharge, which helps to diminish the recurrence of organization and reduction of the portion ward symptoms related to the rehashed organization of Nimodipine. Accordingly, it very well may be presumed that the readied swelling confined framework tablets had the capacity to control the arrival of Nimodipine from the definition at a pre-decided rate for a time of 12 h.

From the data of stability studies, it could be presumed that the improved plans were steady when they were put away for a time of a half year (Momentary solidness study) at a temperature of 40 ± 2 ºC and 75 ± 5% stickiness and A year (Long haul strength study) at a temperature of 25 ± 2 ºC and 60 ± 5% moistness.

CONCLUSION: From the above results and discussion it is concluded that formulation of the sustained-release tablet of Nimodipine containing HPMC K 15M and 200: 23 (in mg) T8 can be taken as a perfect or advanced plan of supported discharge tablets for 24 h discharge as it satisfies every one of the prerequisites for supported discharge tablet and our investigation energizes for the further clinical preliminaries on this definition.

ACKNOWLEDGEMENT: The authors would like to acknowledge the guidance, suggestions, and support from teachers, seniors, and staff members involved in performing the research work.

CONFLICTS OF INTEREST: Nil

REFERENCES:

1. Guleri TK: A review on mouth dissolving tablets. Int Journal of Medi Chem and Analysis 2013: 3(2): 57-65.
2. Dash TR and Verma P: Matrix tablets: An approach towards oral extended-release drug delivery. International Journal of Pharma Res and Review 2013; 2(2): 12-24.
3. Chugh I: Oral sustained drug delivery system: An overview. Int Res Journal of Pharmacy 2012; 3(5): 57-62.
4. Brahmankar DM and Jaiswal B: Controlled release medication Biopharmaceutics and Pharmacokinetics A Treatise. Vallabh Prakashan; Delhi 2009; 398-99.
5. Darandale AS (): Sustained release dosage form: a concise review. Int J Pharm Drug Anal 2017; 5(5): 153-60.
6. Gujral G, Kapoor D and Jaimini M: An update review on modified-release tablets. Journal of Drug Delivery and Therapeutics 2018; 8(4): 5-9.
7. Karvekar M and Khan AB: A Brief review on sustained release matrix-type drug delivery system. Journal of Pharmaceutical Research 2017; 16(3): 282.
8. Dash S: Kinetic modelling on drug release from controlled drug delivery systems. Acta Polaniae Pharmaceutica – Drug research 2010; 67(3): 217-23.

9. Kumar JNS and Gunda RK: Formulation development and evaluation of simvastatin sustained-release tablets. Journal of Pharmaceutical Research 2017; 16 (4): 297.

How to cite this article:
Singh D, Singh D and Chanchal DK: Formulation and *in-vitro* drug release study of controlled release tablet of nimodipine. Int J Pharm Sci & Res 2020; 11(10): 5027-38. doi: 10.13040/IJPSR.0975-8232.11(10).5027-38.